T Cell News and Research

Latest T Cell News and Research

Study identifies multipotent and unipotent stem cells that contribute to prostate postnatal development

Publication in Nature Cell Biology advanced on line publication: researchers at the Université Libre de Bruxelles, ULB identify multipotent and unipotent Stem Cells (SCs) that contribute to prostate postnatal development.

16 Oct 2012

LRRK2 inhibitors may provide neuroprotection for patients with Parkinson's

For decades, patients with Parkinson's disease (PD) have had the same experience. Their hands start to shake uncontrollably, their limbs become rigid and they lose their balance. Years before those movement problems set in, many begin struggling with fainting, incontinence, sexual dysfunction, anxiety and depression. Many patients are still treated with a 42-year-old drug called L-DOPA, which temporarily staves off symptoms but can itself cause heart arrhythmias, stomach bleeding and hallucinations.

16 Oct 2012

Animal research shows promise in treating AD, brain damage and heart problems resulting from SCIs

New animal studies provide additional support for investigating stem cell treatments for Parkinson's disease, head trauma, and dangerous heart problems that accompany spinal cord injury, according to research findings released today.

16 Oct 2012

Gravity changes affect immune system development

New research findings recently published in The FASEB Journal, show that immune system development is affected by gravity changes, as reported by researchers from the University of Lorraine and University of Luxembourg. Astronauts are exposed to stresses, during launch and landing, which disrupts their body's natural defenses against infection. Changes to the immune system need to be investigated before astronauts undergo longer space missions.

16 Oct 2012

Fat cells need sleep to function properly: Study

In a study that challenges the long-held notion that the primary function of sleep is to give rest to the brain, researchers have found that not getting enough shut-eye has a harmful impact on fat cells, reducing by 30 percent their ability to respond to insulin, a hormone that regulates energy.

16 Oct 2012

Maryland scientists create stem cell model for Gaucher disease

A new method of using adult stem cells as a model for the hereditary condition Gaucher disease could help accelerate the discovery of new, more effective therapies for this and other conditions such as Parkinson's, according to new research from the University of Maryland School of Medicine.

16 Oct 2012

Researchers use cell phone data to track malaria spread in Kenya

"Harvard researchers found they could track the spread of malaria in Kenya using phone calls and text messages from 15 million mobile phones," ABC News' "Medical Unit" reports.

16 Oct 2012

Thymic stromal lymphopoietin molecule makes mice resistant to skin cancer

A molecule involved in asthma and allergies has now been shown to make mice resistant to skin cancer, according to scientists at Washington University School of Medicine in St. Louis.

16 Oct 2012

Researcher uncovers mechanisms involved in prognosis of acute myeloid leukemia

When patients suffering from Acute Myeloid Leukemia (AML) express high levels of the gene, MN1, an already aggressive leukemia is accelerated and shortens survival time. While that's a known fact, the mechanisms involved aren't well understood which is why a Wake Forest Baptist Medical Center researcher decided to take a closer look.

16 Oct 2012

VeriStrat identifies NSCLC patients likely to respond to erlotinib

A study, published in the November 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, showed the plasma test VeriStrat can predict response but not survival benefit from erlotinib. The study was conducted on a subset of patients enrolled in the NCIC Clinical Trials Group, BR.21 phase III trial of erlotinib versus placebo in previously treated advanced non-small cell lung cancer patients.

16 Oct 2012

Fit elderly NSCLC patients should be considered for salvage targeted therapy

Until there are more validated biomarkers to direct treatment decisions, many physicians use patient age to decide what therapy to give their patients. Literature data report that older patients often go undertreated because of concerns for limited tolerance to toxic therapies.

16 Oct 2012

GILZ protein encourages bone growth in mouse model

Georgia Health Sciences University researchers have developed a mouse that errs on the side of making bone rather than fat, which could eventually lead to better drugs to treat inflammatory diseases such as rheumatoid arthritis.

16 Oct 2012

Study demonstrates how new scientific knowledge drives novel treatments for spinal cord injuries

Research released today demonstrates how new scientific knowledge is driving innovative treatments for spinal cord injuries. Spinal cord damage is debilitating and life-altering, limiting or preventing movement and feeling for millions worldwide, and leading to chronic health conditions and pain.

16 Oct 2012

NIH to accelerate development and application of single cell analysis across various fields

The National Institutes of Health plans to invest more than $90 million over five years, contingent upon the availability of funds, to accelerate the development and application of single cell analysis across a variety of fields.

16 Oct 2012

Rapamycin may delay onset of Parkinson's or AD

Rapamycin, a drug used to prevent rejection in transplants, could delay the onset of neurodegenerative diseases such as Alzheimer's and Parkinson's.

16 Oct 2012

Preclinical study finds how fat tissue fuels cancer growth

Fat progenitor cells may contribute to cancer growth by fortifying the vessels that provide needed blood to tumors, according to preclinical research findings by investigators at The University of Texas Health Science Center at Houston (UTHealth).

16 Oct 2012

HIV agent offers HER2-positive breast cancer hope

A drug used to treat HIV infection may be a new treatment line for patients with an aggressive type of breast cancer, US researchers believe.

15 Oct 2012

Enrollment complete in Idera's IMO-3100 Phase 2 trial for psoriasis

Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.

15 Oct 2012

Regulatory B cells may provide effective treatment for severe autoimmune diseases

Reproducing a rare type of B cell in the laboratory and infusing it back into the body may provide an effective treatment for severe autoimmune diseases such as multiple sclerosis or rheumatoid arthritis, according to researchers at Duke University Medical Center.

15 Oct 2012

White blood cell variation can help predict non-blood cancers

Postdoctoral Research Fellow Devin Koestler is a biostatistician in the Geisel School of Medicine at Dartmouth. He develops and applies statistical methods to large volumes of data, seeking new approaches for understanding disease, cancer in particular. Koestler and his colleagues are investigating the potential use of white blood cell variation as a diagnostic, predictive, and research tool in the study of non-blood cancers.

15 Oct 2012